Abstract
Purpose
This study evaluated PX-12, a novel small molecule inhibitor of the proto-oncogene (Trx-1), in patients with previously treated advanced pancreatic cancer (APC).
Methods
PX-12 (54 or 128 mg/m2) was administered by 3-hour IV infusion daily ×5 days every 21 days (n = 17). Patients were randomized to either 54 or 128 mg/m2 and then stratified based on CA 19-9 level (≥1,000 vs. <1,000 U/ml) and SUV values on PET scans (≥7.0 vs. <7.0). The primary endpoint was based on a progression-free survival (PFS) at 4 months in ≥40% of patients, and required 40 patients in each arm. An amendment required elevated Trx-1 levels (>18 ng/ml) as an entry criteria after the first 17 patients were accrued.
Results
Plasma Trx-1 levels were elevated in 3/28 (11%) patients screened for study. The grade of the expired metabolite odor was higher in the 128 mg/m2 arm. Therapy was well tolerated, and Grade ≥3 adverse events were uncommon. The best response was stable disease in 2 patients. There was no consistent decrease in SUV, Trx-1 levels or CA 19-9 levels with therapy. No patients had a PFS of >4 months. Median PFS and survival were 0.9 months (95% CI 0.5–1.2) and 3.2 months (95% CI 2.4–4.2), respectively.
Conclusions
Due to the lack of significant antitumor activity and unexpectedly low baseline Trx-1 levels, the study was terminated early. PX-12 does not appear to be active in unselected patients with previously treated APC.
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J et al (2005) Global Cancer Statistics, 2002. CA Cancer J Clin 55:74–108
Rivera F, Lopez-Tarruella S, Vega-Villegas ME et al (2009) Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 35:335–339
Rocha-Lima CM (2008) New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs 19:435–446
Hilbig A, Oettle H (2008) Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev Anticancer Ther 8:511–523
Sultana A, Smith CT, Cunningham D et al (2007) Meta-analysis of chemotherapy. J Clin Oncol 25:2607–2615
Almhanna K, Kim R (2008) Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard? Oncology 22:1176–1196
Pelzer U, Kubica K, Stieler J et al. (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 (May 20 suppl; abstr 4508)
Brell JM, Matin K, Evans T (2009) Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 76:270–274
Powis G, Kirkpatrick DL (2007) Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7:392–397
Kontou M, Will RD, Adelfalk C et al (2004) Thioredoxin, a regulator of gene expression. Oncogene 23:2146–2152
Grogan T, Fenoglio-Priser C, Zaheb R et al (2000) Overexpression of thioredoxin, a putative oncogene, in gastric carcinoma with associated change in proliferation and apoptosis. J Pathol 31:475–481
Nakamura H, Bai J, Nishinaka Y et al (2000) Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24:53–60
Seo Y, Baba H, Fukuda T et al (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88:2239–2245
Raffel J, Bhattacharyya AK, Cui H et al (2003) Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142:46–51
Kirkpatrick DL, Hiscox A, Boice M, et al. (2008) Screening plasma thioredoxin (Trx-1) to potentially guide clinical development of the Trx-1 inhibitor PX-12. EORTC-NCI-AACR symposium on “Molecular targets and cancer therapeutics”, Geneva, Switzerland, Abstract #108
Welsh S, Bellamy WT, Briehl MM et al (2002) The recox protein thioredoxin-1 is necessary for the hypoxia dependent increase in HIF-1a and results in increased vascular endothelial growth factor formation by cancer cells and enhanced tumor angiogenesis. Cancer Res 62:5089–5095
Semenza Gl (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35:71–103
Kirkpatrick D, Kuperus M, Dowdeswell M et al (1998) Mechanism of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 55:987–994
Ramanathan RK, Kirkpatrick DL, Belani CP et al (2007) A phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 13:2109–2114
Von Hoff DD, Korn R, Mousses S (2009) Pancreatic cancer—could it be that simple? A different context of vulnerability. Cancer Cell 16:7–8
Komar G, Kauhanen S, Liukko K et al (2009) Decreased blood flow with increased metabolic activity: a novel sign of pancreatic cancer tumor aggressiveness. Clin Cancer Res 15:5511–5517
Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. EORTC Pet Study Group. Eur J Cancer 35:1773–1782
Von Hoff DD, Ramanathan RK, Borad M et al (2009) SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 27:15s (suppl; abstr 4525)
Hess V, Glimelius B, Grawe P et al (2008) CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomized controlled trial. Lancet Oncol 9:132–138
Nakai Y, Kawabe T, Isayama H et al (2008) CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology 75:120–126
Ramanathan RK, Dragovich T, Richards D et al (2009) Results from phase Ib studies of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies. J Clin Oncol 27:15s (suppl; abstr 2571)
Callister ME, Burke‐Gaffney A, Quinlan GJ et al (2006) Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 61:521–527
Abdiu A, Nakamura H, Sahaf B et al (2000) Thioreodxoin blood level increases after servere burn injury. Antioxid Redox Signal 2:707–716
Leaver SK, MacCallum NS, Pingle V et al (2010) Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor. Instensive Care Med 36:336–341
Jikimoto T, Nishikubo Y, Koshiba M et al (2002) Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 38:765–772
Jekell A, Hossain A, Alehagen U et al (2004) Elevated circulating levels of thioredoxin and satress in chronic heart failure. Eur J Heart Fail 6:883–890
Takahashi K, Chin K, Nakamura H et al (2008) Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid Redox Signal 10:715–726
Marumoto M, Suzuki S, Hosono A et al (2009) Changes in thiordoxin concentrations: an observation in an ultra-marathon race. Environ Heatlth Prev Med. December 2 [Epub ahead of print]
Fu JN, Li J, Tan Q et al (2010) Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. Invest New Drugs March 2 [Epub ahead of print]
Arnold NB, Ketterer K, Kleeff J et al (2004) Thioredoxin is downstream of smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Cancer Res 64:3599–3606
Acknowledgments
The authors thank Nina Cantafio for editorial assistance. Dr. Sylvan Green (deceased) for statistical assistance in designing this study. Alton Hiscox, Michael Boice at Prolx Pharmaceuticals for ELISA analysis. Michele Avery for secretarial analysis. Supported in part by grants from NCI: P01 CA109552, R44CA075923 and ProlX Pharmaceuticals. Study identifier: NCT00177242.
Author information
Authors and Affiliations
Corresponding author
Additional information
Sylvan Green: Deceased.
Rights and permissions
About this article
Cite this article
Ramanathan, R.K., Abbruzzese, J., Dragovich, T. et al. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 67, 503–509 (2011). https://doi.org/10.1007/s00280-010-1343-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-010-1343-8